

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104  
 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
 or Section 30(h) of the Investment Company Act of 1940

<b>1. Name and Address of Reporting Person*</b> <u>Huller Kelly</u>  (Last) (First) (Middle) <u>VALLEY FORGE BUSINESS CENTER</u> <u>2560 GENERAL ARMISTEAD AVENUE</u>  (Street) <u>AUDUBON PA 19403</u>  (City) (State) (Zip)	<b>2. Date of Event Requiring Statement (Month/Day/Year)</b> <u>02/27/2019</u>	<b>3. Issuer Name and Ticker or Trading Symbol</b> <u>GLOBUS MEDICAL INC [ GMED ]</u>  <b>4. Relationship of Reporting Person(s) to Issuer (Check all applicable)</b> Director <span style="margin-left: 100px;">10% Owner</span> <input checked="" type="checkbox"/> Officer (give title below) <span style="margin-left: 100px;">Other (specify below)</span> <p style="text-align: center;"><u>SVP, General Counsel</u></p>	<b>5. If Amendment, Date of Original Filed (Month/Day/Year)</b>  <b>6. Individual or Joint/Group Filing (Check Applicable Line)</b> <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Class A Common Stock</u>	<u>15,384</u>	<u>D</u>	

### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
<u>Stock Option (Right to Buy Class A Common Stock)</u>	<u>(1)</u>	<u>06/16/2020</u>	<u>Class A Common Stock</u>	<u>3,076</u>	<u>11.86</u>	<u>D</u>
<u>Stock Option (Right to Buy Class A Common Stock)</u>	<u>(2)</u>	<u>02/11/2021</u>	<u>Class A Common Stock</u>	<u>23,076</u>	<u>11.28</u>	<u>D</u>
<u>Stock Option (Right to Buy Class A Common Stock)</u>	<u>(3)</u>	<u>08/29/2022</u>	<u>Class A Common Stock</u>	<u>2,500</u>	<u>15.34</u>	<u>D</u>
<u>Stock Option (Right to Buy Class A Common Stock)</u>	<u>(4)</u>	<u>01/30/2023</u>	<u>Class A Common Stock</u>	<u>7,500</u>	<u>12.59</u>	<u>D</u>
<u>Stock Option (Right to Buy Class A Common Stock)</u>	<u>(5)</u>	<u>03/04/2024</u>	<u>Class A Common Stock</u>	<u>7,500</u>	<u>24.9</u>	<u>D</u>
<u>Stock Option (Right to Buy Class A Common Stock)</u>	<u>(6)</u>	<u>04/01/2025</u>	<u>Class A Common Stock</u>	<u>7,500</u>	<u>25.8</u>	<u>D</u>
<u>Stock Option (Right to Buy Class A Common Stock)</u>	<u>(7)</u>	<u>02/02/2026</u>	<u>Class A Common Stock</u>	<u>7,500</u>	<u>24.21</u>	<u>D</u>
<u>Stock Option (Right to Buy Class A Common Stock)</u>	<u>(8)</u>	<u>02/02/2027</u>	<u>Class A Common Stock</u>	<u>7,500</u>	<u>25.96</u>	<u>D</u>
<u>Stock Option (Right to Buy Class A Common Stock)</u>	<u>(9)</u>	<u>02/02/2028</u>	<u>Class A Common Stock</u>	<u>10,000</u>	<u>45.64</u>	<u>D</u>
<u>Stock Option (Right to Buy Class A Common Stock)</u>	<u>(10)</u>	<u>01/22/2029</u>	<u>Class A Common Stock</u>	<u>40,000</u>	<u>43.58</u>	<u>D</u>

**Explanation of Responses:**

1. These options were granted on June 16, 2010 and are fully vested.
2. These options were granted on February 11, 2011 and are fully vested.
3. These options were granted on August 29, 2012 and are fully vested.
4. These options were granted on January 30, 2013 and are fully vested.
5. These options were granted on March 4, 2014 and are fully vested.
6. These options were granted on April 1, 2015 and are fully vested.
7. These options were granted on February 2, 2016, and vest over a four-year period with one-fourth(1/4) of the options granted vesting on January 1, 2017, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.
8. These options were granted on February 2, 2017, and vest over a four-year period with one-fourth(1/4) of the options granted vesting on January 1, 2018, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.
9. These options were granted on February 2, 2018, and vest over a four-year period with one-fourth(1/4) of the options granted vesting on January 1, 2019, the first anniversary of the vesting commencement

date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.

10. These options were granted on January 22, 2019, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2020, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.

**Remarks:**

/s/ Kelly G. Huller

03/06/2019

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

Know all by these presents that the undersigned hereby constitutes and appoints Adam M. Cole, acting alone, signing singly, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% or more stockholder of Globus Medical, Inc. (the "Company"), Forms ID, 3, 4, 5 and Update Passphrase Acknowledgement (and any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "1934 Act"), and the rules promulgated thereunder; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form ID, 3, 4, 5 and Update Passphrase Acknowledgement (and any amendments thereto) and to file timely such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and (3) take any other action of any type whatsoever in connection with the foregoing which in the opinion of such attorney-in-fact may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the 1934 Act.

This Power of Attorney revokes any and all prior powers of attorney and shall remain in full force and effect until the undersigned is no longer required to file Forms ID, 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 5 day of March 2019.

/s/ Kelly G. Huller  
Kelly G. Huller